GlassScriptPhysician profile
Marwan A Takieddine
NPI 1023099132
$7,509.04
in general payments reported to CMS, 2019-2025
31 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,192 · 2020: $419 · 2021: $556 · 2022: $737 · 2023: $1,336 · 2024: $1,836 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,591 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,591.38 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,368.91 | 2019-2025 | Lokelma, Farxiga |
| Opko Pharmaceuticals, LLC | $1,014.66 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $841.01 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $588.45 | 2019-2025 | |
| Amgen INC. | $472.65 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Vifor Pharma, INC. | $462.20 | 2019-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $421.17 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $338.45 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.81 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $203.13 | 2019-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $181.35 | 2022-2025 | Lupkynis |
| Horizon Therapeutics Plc | $145.59 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.67 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $124.10 | 2020-2024 | Benlysta |
| Lilly USA, LLC | $118.69 | 2024-2025 | Jardiance |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $110.81 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $100.89 | 2022-2025 | Terlivaz, Acthar |
| Novo Nordisk INC | $94.81 | 2022-2024 | Ozempic, Rybelsus |
| Amicus Therapeutics, INC. | $89.52 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $75.58 | 2023 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $65.73 | 2019-2024 | Ultomiris |
| Daiichi Sankyo INC. | $51.30 | 2020-2023 | Injectafer |
| Ardelyx, INC. | $44.80 | 2023-2024 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.99 | 2022-2024 | Jynarque |
| Pharmacosmos Therapeutics INC. | $37.94 | 2021-2022 | |
| Chiesi USA, INC. | $35.43 | 2025 | Elfabrio |
| Janssen Pharmaceuticals, INC | $30.36 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.88 | 2021 | |
| Genentech USA, INC. | $15.88 | 2019 | |
| Cormedix INC. | $14.48 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $13.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marwan Takieddine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.